By Y. Peter Kang ( March 24, 2016, 8:48 PM EDT) -- A California federal jury found on Thursday that Gilead Sciences must pay $200 million to rival Merck for infringing two patents covering a key ingredient used in Gilead's blockbuster hepatitis C drugs, an award that fell short of the $2 billion Merck had been seeking....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.